204 related articles for article (PubMed ID: 38245249)
1. The pathogenesis of Parkinson's disease.
Morris HR; Spillantini MG; Sue CM; Williams-Gray CH
Lancet; 2024 Jan; 403(10423):293-304. PubMed ID: 38245249
[TBL] [Abstract][Full Text] [Related]
2. Parkinson's disease and the gut: Models of an emerging relationship.
Bindas AJ; Kulkarni S; Koppes RA; Koppes AN
Acta Biomater; 2021 Sep; 132():325-344. PubMed ID: 33857691
[TBL] [Abstract][Full Text] [Related]
3. Advances in understanding the function of alpha-synuclein: implications for Parkinson's disease.
Calabresi P; Di Lazzaro G; Marino G; Campanelli F; Ghiglieri V
Brain; 2023 Sep; 146(9):3587-3597. PubMed ID: 37183455
[TBL] [Abstract][Full Text] [Related]
4. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
5. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.
Murphy KE; Gysbers AM; Abbott SK; Tayebi N; Kim WS; Sidransky E; Cooper A; Garner B; Halliday GM
Brain; 2014 Mar; 137(Pt 3):834-48. PubMed ID: 24477431
[TBL] [Abstract][Full Text] [Related]
6. Review: Sporadic Parkinson's disease: development and distribution of α-synuclein pathology.
Del Tredici K; Braak H
Neuropathol Appl Neurobiol; 2016 Feb; 42(1):33-50. PubMed ID: 26662475
[TBL] [Abstract][Full Text] [Related]
7. α-Synuclein and Lewy pathology in Parkinson's disease.
Kalia LV; Kalia SK
Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
[TBL] [Abstract][Full Text] [Related]
8. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein?
Pozo Devoto VM; Falzone TL
Dis Model Mech; 2017 Sep; 10(9):1075-1087. PubMed ID: 28883016
[TBL] [Abstract][Full Text] [Related]
10. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease.
Kelly LP; Carvey PM; Keshavarzian A; Shannon KM; Shaikh M; Bakay RA; Kordower JH
Mov Disord; 2014 Jul; 29(8):999-1009. PubMed ID: 24898698
[TBL] [Abstract][Full Text] [Related]
11. Targeting α-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease.
Haque ME; Akther M; Azam S; Kim IS; Lin Y; Lee YH; Choi DK
Br J Pharmacol; 2022 Jan; 179(1):23-45. PubMed ID: 34528272
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
George S; Brundin P
J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
[TBL] [Abstract][Full Text] [Related]
13. The immunology of Parkinson's disease.
Zhu B; Yin D; Zhao H; Zhang L
Semin Immunopathol; 2022 Sep; 44(5):659-672. PubMed ID: 35674826
[TBL] [Abstract][Full Text] [Related]
14. Heat shock protein 70 reduces α-synuclein-induced predegenerative neuronal dystrophy in the α-synuclein viral gene transfer rat model of Parkinson's disease.
Moloney TC; Hyland R; O'Toole D; Paucard A; Kirik D; O'Doherty A; Gorman AM; Dowd E
CNS Neurosci Ther; 2014 Jan; 20(1):50-8. PubMed ID: 24279716
[TBL] [Abstract][Full Text] [Related]
15. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
[TBL] [Abstract][Full Text] [Related]
16. Prying into the Prion Hypothesis for Parkinson's Disease.
Brundin P; Melki R
J Neurosci; 2017 Oct; 37(41):9808-9818. PubMed ID: 29021298
[TBL] [Abstract][Full Text] [Related]
17. The concept of alpha-synuclein as a prion-like protein: ten years after.
Steiner JA; Quansah E; Brundin P
Cell Tissue Res; 2018 Jul; 373(1):161-173. PubMed ID: 29480459
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic approaches to target alpha-synuclein pathology.
Brundin P; Dave KD; Kordower JH
Exp Neurol; 2017 Dec; 298(Pt B):225-235. PubMed ID: 28987463
[TBL] [Abstract][Full Text] [Related]
19. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
20. Viral mimetic priming enhances α-synuclein-induced degeneration: Implications for Parkinson's disease.
Olsen LK; Cairns AG; Ådén J; Moriarty N; Cabre S; Alamilla VR; Almqvist F; Dowd E; McKernan DP
Brain Behav Immun; 2019 Aug; 80():525-535. PubMed ID: 31029796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
